HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models.

AbstractUNLABELLED:
Common pharmacological treatments of neuropathic and chronic inflammatory pain conditions generally lack efficacy and/or are associated with significant untoward side effects. However, recent preclinical data indicate that combined inhibition of cyclooxygenase (COX) and fatty acid amide hydrolase (FAAH), the primary catabolic enzyme of the endocannabinoid N-arachidonoylethanolamine (anandamide; AEA), produces enhanced antinociceptive effects in a variety of murine models of pain. Accordingly, the primary objective of the present study was to investigate the consequences of co-administration of the COX inhibitor diclofenac and the highly selective FAAH inhibitor PF-3845 in models of neuropathic pain (i.e., chronic constrictive injury of the sciatic nerve (CCI)) and inflammatory pain induced by an intraplantar injection of carrageenan. Here, we report that combined administration of subthreshold doses of these drugs produced enhanced antinociceptive effects in CCI and carrageenan pain models, the latter of which was demonstrated to require both CB1 and CB2 receptors. The combined administration of subthreshold doses of these drugs also increased AEA levels and decreased prostaglandin levels in whole brain. Together, these data add to the growing research that dual blockade of FAAH and COX represents a potential therapeutic strategy for the treatment of neuropathic and inflammatory pain states.
PERSPECTIVE:
Tandem inhibition of FAAH and COX attenuates inflammatory and neuropathic pain states, which may avoid potentially harmful side effects of other therapeutic options, such as NSAIDs or opioids.
AuthorsTravis W Grim, Sudeshna Ghosh, Ku-Lung Hsu, Benjamin F Cravatt, Steven G Kinsey, Aron H Lichtman
JournalPharmacology, biochemistry, and behavior (Pharmacol Biochem Behav) Vol. 124 Pg. 405-11 (Sep 2014) ISSN: 1873-5177 [Electronic] United States
PMID25058512 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Inc. All rights reserved.
Chemical References
  • Enzyme Inhibitors
  • Prostaglandin-Endoperoxide Synthases
  • Amidohydrolases
  • fatty-acid amide hydrolase
Topics
  • Amidohydrolases (antagonists & inhibitors)
  • Animals
  • Disease Models, Animal
  • Enzyme Inhibitors (pharmacology, therapeutic use)
  • Hyperalgesia (drug therapy)
  • Inflammation (drug therapy)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuralgia (drug therapy)
  • Prostaglandin-Endoperoxide Synthases (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: